After MURANO: Roche/AbbVie Map Venclexta's Expansion Past CLL

Sponsors expect that if Venclexta demonstrates compelling early data in new indications – like acute myeloid leukemia and multiple myeloma – the US FDA will be willing to help speed access for patients.

BCL-2 protein_164970335_1200.jpg
The BCL-2 protein, illustrated above, prevents cell death and is often over-expressed in cancer cells.

Withthe MURANO study of the first-in-class BCL-2 inhibitor Venclexta in the broad relapsed chronic lymphocytic leukemia population done and dusted and front-line studies chugging along, partners Roche and AbbVie Inc. are busy writing the drug's next chapters, with a special focus on expansion into acute myeloid leukemia and multiple myeloma.

Venclexta (venetoclax) is an oral drug that blocks the BCL-2 protein in order to restore the signaling system that tells...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category